735 related articles for article (PubMed ID: 26273621)
21. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.
Dongiovanni P; Romeo S; Valenti L
World J Gastroenterol; 2014 Sep; 20(36):12945-55. PubMed ID: 25278690
[TBL] [Abstract][Full Text] [Related]
22. Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables.
Vespasiani-Gentilucci U; Gallo P; Dell'Unto C; Volpentesta M; Antonelli-Incalzi R; Picardi A
World J Gastroenterol; 2018 Nov; 24(43):4835-4845. PubMed ID: 30487694
[TBL] [Abstract][Full Text] [Related]
23. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.
Akuta N; Kawamura Y; Arase Y; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Ikeda K; Kumada H
Gut Liver; 2016 May; 10(3):437-45. PubMed ID: 26610348
[TBL] [Abstract][Full Text] [Related]
24. Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update.
Valenti LVC; Baselli GA
Curr Pharm Des; 2018; 24(38):4566-4573. PubMed ID: 30659533
[TBL] [Abstract][Full Text] [Related]
25. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
[TBL] [Abstract][Full Text] [Related]
26. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
Borén J; Adiels M; Björnson E; Matikainen N; Söderlund S; Rämö J; Ståhlman M; Ripatti P; Ripatti S; Palotie A; Mancina RM; Hakkarainen A; Romeo S; Packard CJ; Taskinen MR
JCI Insight; 2020 Dec; 5(24):. PubMed ID: 33170809
[TBL] [Abstract][Full Text] [Related]
27. Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease.
Anstee QM; Seth D; Day CP
Gastroenterology; 2016 Jun; 150(8):1728-1744.e7. PubMed ID: 26873399
[TBL] [Abstract][Full Text] [Related]
28. Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.
Newberry EP; Hall Z; Xie Y; Molitor EA; Bayguinov PO; Strout GW; Fitzpatrick JAJ; Brunt EM; Griffin JL; Davidson NO
Hepatology; 2021 Sep; 74(3):1203-1219. PubMed ID: 33638902
[TBL] [Abstract][Full Text] [Related]
29. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
[TBL] [Abstract][Full Text] [Related]
30. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
[TBL] [Abstract][Full Text] [Related]
31. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
[TBL] [Abstract][Full Text] [Related]
32. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.
Valenti L; Alisi A; Galmozzi E; Bartuli A; Del Menico B; Alterio A; Dongiovanni P; Fargion S; Nobili V
Hepatology; 2010 Oct; 52(4):1274-80. PubMed ID: 20648474
[TBL] [Abstract][Full Text] [Related]
33. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
34. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
Wang CW; Lin HY; Shin SJ; Yu ML; Lin ZY; Dai CY; Huang JF; Chen SC; Li SS; Chuang WL
Liver Int; 2011 Oct; 31(9):1326-31. PubMed ID: 21745282
[TBL] [Abstract][Full Text] [Related]
35. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.
Anstee QM; Day CP
Semin Liver Dis; 2015 Aug; 35(3):270-90. PubMed ID: 26378644
[TBL] [Abstract][Full Text] [Related]
36. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
[TBL] [Abstract][Full Text] [Related]
37. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis of non-alcoholic fatty liver disease (NAFLD).
Yki-Järvinen H
Diabetologia; 2016 Jun; 59(6):1104-11. PubMed ID: 27091184
[TBL] [Abstract][Full Text] [Related]
39. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Kramer JA; Grindley J; Crowell AM; Makaron L; Kohli R; Kirby M; Mansfield KG; Wachtman LM
Vet Pathol; 2015 Mar; 52(2):404-13. PubMed ID: 24913270
[TBL] [Abstract][Full Text] [Related]
40. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant.
Mancina RM; Matikainen N; Maglio C; Söderlund S; Lundbom N; Hakkarainen A; Rametta R; Mozzi E; Fargion S; Valenti L; Romeo S; Taskinen MR; Borén J
J Clin Endocrinol Metab; 2015 May; 100(5):E821-5. PubMed ID: 25763607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
